OF THE PROBLEM THE pharmaceutical market in India today is worth Rs.57206 crores up from Rs. 5000 crores in 1995*. It is one of the fastest growing markets with a growth rate of around 15%. India has a large number of Pharmaceutical companies which operate in an environment of high competition. The competition is even higher in a high generic market like in India where drugs are in fierce price competition. It is estimated that there are around 20‚000 pharmaceutical companies* in India‚ competing
Premium Physician Pharmacology Medicine
services and goods across geopolitical boundaries‚ including low cost skilled labor‚ low cost raw materials‚ tax benefits‚ and price breaks. Whelan Pharmaceutical was the best example to illustrate how the company chose the best manufacturing site for global sourcing from different perspectives. Whelan was an American multinational pharmaceutical corporation‚ headquartered in Maryland. The main goal of the case was to examine and analyze potential manufacturing sites for Whelan’s new product Varex®
Premium Tax Switzerland United Kingdom
RiDUCES and Competitor Analysis Pfizer‚ Inc: Branded Pharmaceutical Industry-Oncology Pharmaceuticals Executive Summary The value that the branded pharmaceutical industry adds to the US economy is growing slower than US GDP (Snyder‚ 2012). Rivalry has intensified while the rate of blockbuster drug development has slowed due to an increase in regulation from the government and the industry trade association‚ PhRMA. The number of new entrants is fairly low and some are exiting or consolidating through
Premium Pharmaceutical industry Pharmacology Novartis
roses. From the inception in 1958‚ it has today burgeoned into one of the top line conglomerates in Bangladesh. Square Pharmaceuticals Ltd.‚ the flagship company‚ is holding the strong leadership position in the pharmaceutical industry of Bangladesh since 1985 and is now on its way to becoming a high performance global player. SQUARE Pharmaceuticals Limited is the largest pharmaceutical company in Bangladesh and it has been continuously in the 1st position among all national and multinational companies
Premium Pharmaceutical industry Pharmacology Limited company
Project Corporate finance Project Sun pharmaceuticals Sun pharmaceuticals Submitted to : Prof. S.Ramesh Submitted by : Shamili.M (FPB1214/125) Submitted to : Prof. S.Ramesh Submitted by : Shamili.M (FPB1214/125) Type | Public | Traded as | BSE : 524715 NSE: sunpharma | Industry | Pharmaceuticals | Founded | 1983 | Founder | Dilip
Premium Pharmaceutical industry Pharmacology
SCM–027416 (MFP/2014-05) TABLE OF CONTENTS INDEX PAGE NO. Executive Summary………………………………………………………….……………………4 Section 1 CIPLA (Pharmaceutical Company) Introduction…………………………………………………………………..……………………5 Section 2 PESTLE ANALYSIS 2.1 Political and Legal factors……...………………………..…………………………………....7 2.2 Economical factors…………………………………………………………………………....8 2.3 Social-cultural factors…………
Premium Strategic management Generic drug Pharmaceutical industry
resources. ➢ If equal gender opportunity for all female pharmacists during offering and recruiting in jobs especially in Pharmaceutical Industry. ➢ If we have a full-fledged specialized Pharmaceutical University‚ doctorial & Post-Doc level offering specialized Research based courses like New Drug Design‚ Innovative New Process & Analysis Technology. ➢ If Giant Pharmaceutical Industry open Pharmacy University with continual training of students from first year to final year‚ and finally recruiting
Premium Pharmacy Pharmacology
the cost-plus markup in China is in the 60 to 70 percent range (including VAT)‚ compared with ranges of about 10 to 20 percent for the United States‚ and about 20 to 25 percent for Japan. vii China Health Policy Notes‚ No. 1 While pharmaceutical cost containment has mostly focused on government-directed price control‚ other approaches are increasingly being explored. Many new policy levers are being considered and tested—for example‚ reforming the payment system from fee-forservice
Premium Medicine Health care Government
PHARMACEUTICALS INDUSTRY ANALYSIS –USING MAY & BAKER NIGERIA PLC. EMBA 14A GROUP 8 MEMBERS IFEYINWA OKONKWO TINA EBUEHI ADEWALE ADEDIRAN BOLA ADEROGBA ADEROGBA TAIWO OLUTOBI OLUFUNWA IFEANYI IBE 2010 8/13/2010 OVERVIEW Pharmaceuticals companies are very vital to the health care delivery systems in every country of the world. These companies are licensed to market‚ develop‚ research and distribute drugs for the prevention‚ treatment and cur of diseases and other medical conditions
Premium Pharmaceutical industry Pharmacology
CSR COMMUNICATION IN THE PHARMACEUTICAL INDUSTRY AN ANALYSIS OF THE WEBSITES OF THREE PHARMACEUTICAL WHOLESALERS MASTER THESIS Author: José Javier Levrino (JL82847) Supervisor: Anne Ellerup Nielsen MA in Corporate Communication Århus‚ Denmark. August 2010 CSR COMMUNICATION IN THE PHARMACEUTICAL INDUSTRY José Javier Levrino Table of contents Abstract 1. Introduction 1.1 Motivation 1.2 Problem statement 1.3 Delimitation 1.4 Methodology 1.4.1 1.4.2 1.4.3 1.4.4 Scientific paradigm: hermeneutics
Premium Corporate social responsibility Communication Public relations